Rivaroxaban and apixaban demonstrated similar effectiveness and safety for the treatment of cancer-associated venous thromboembolism through 6 months in patients at lower risk of bleeding.
Does rivaroxaban compared to apixaban reduce the composite of recurrent VTE or bleeding-related hospitalization in adult patients with cancer-associated VTE at lower risk of bleeding?
In a real-world cohort of patients with cancer-associated VTE at lower bleeding risk, rivaroxaban and apixaban demonstrated similar effectiveness and safety at 3 and 6 months.
Absolute Event Rate: 0% vs 0%
Rivaroxaban and apixaban have similar effectiveness and safety for treatment of cancer-associated VTE through 6 months.Clinicians should therefore consider patient preference and adherence when choosing the optimal anticoagulant.
Caroti et al. (Sat,) reported a other. Rivaroxaban and apixaban demonstrated similar effectiveness and safety for the treatment of cancer-associated venous thromboembolism through 6 months in patients at lower risk of bleeding.